Dimenhydrinate - Generic Drug Details

What are the generic drug sources for dimenhydrinate and what is the scope of patent protection?

Dimenhydrinate is the generic ingredient in one branded drug marketed by Baxter Hlthcare, Fresenius Kabi Usa, Watson Labs, Watson Labs Teva, Wyeth Ayerst, Alra, Heather, and Nexgen Pharma Inc, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for dimenhydrinate. One supplier is listed for this compound.

Summary for dimenhydrinate

US Patents:	0
Tradenames:	1
Applicants:	8
NDAs:	9
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	23
Patent Applications:	6,139
Drug Prices:	Drug price trends for dimenhydrinate
What excipients (inactive ingredients) are in dimenhydrinate?	dimenhydrinate excipients list
DailyMed Link:	dimenhydrinate at DailyMed

See drug prices for dimenhydrinate

Recent Clinical Trials for dimenhydrinate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mount Sinai Hospital, Canada	PHASE2
Preeyaporn Jirakittidul	NA
The University of The West Indies	Early Phase 1

See all dimenhydrinate clinical trials

Medical Subject Heading (MeSH) Categories for dimenhydrinate

Antiemetics

Histamine H1 Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for dimenhydrinate

R06AA	Aminoalkyl ethers
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

US Patents and Regulatory Information for dimenhydrinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	DIMENHYDRINATE	dimenhydrinate	TABLET;ORAL	085166-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Wyeth Ayerst	DIMENHYDRINATE	dimenhydrinate	INJECTABLE;INJECTION	084316-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Nexgen Pharma Inc	DIMENHYDRINATE	dimenhydrinate	TABLET;ORAL	085985-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Alra	DIMENHYDRINATE	dimenhydrinate	LIQUID;ORAL	080715-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs Teva	DIMENHYDRINATE	dimenhydrinate	INJECTABLE;INJECTION	080615-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Dimenhydrinate Market Analysis and Financial Projection

Last updated: February 14, 2026

What are the market dynamics for dimenhydrinate?

Dimenhydrinate, an antihistamine with antiemetic properties, primarily treats motion sickness, nausea, and vertigo. It remains a common over-the-counter (OTC) medication in many regions, especially in North America and Europe. Its market is influenced by several factors:

Demand Drivers:

• Prevalence of motion sickness and nausea: Increased travel, especially during holiday seasons and post-pandemic recovery, sustains steady demand.
• Aging populations: Elderly populations are more susceptible to vertigo and nausea, maintaining chronic demand.
• Over-the-counter sales: Its OTC classification facilitates broad access, supporting consistent sales volumes.

Market Constraints:

• Competition from newer agents: Alternatives like meclizine and promethazine offer similar efficacy with different side-effect profiles.
• Regulatory shifts: Potential reclassification from OTC to prescription status could reduce market reach.
• Side effect profile: Drowsiness and anticholinergic effects limit use in some patient groups, impacting usage rates.

Regional Variability:

• In North America, OTC availability promotes higher sales.
• In European markets, regulatory tightening has led to shifts toward prescribed formulations.

How does the financial trajectory of dimenhydrinate appear?

Quantitative analyses rely on sales data, market size estimates, and competitive positioning:

Market Size Estimates

• The global OTC antiemetic market was valued at approximately $850 million in 2022, with dimenhydrinate accounting for about 30% of the antiemetic OTC segment, equating roughly to $255 million (source: MarketsandMarkets).

Revenue Trends

• The market experienced a compound annual growth rate (CAGR) of approximately 3% from 2018 to 2022.
• Growth prospects remain moderate owing to saturation in mature markets; however, emerging markets show potential due to increasing travel and OTC medication acceptance.

Key Players and Market Share

Company	Market Share (approximate)	Key Products
Johnson & Johnson (Dramamine)	40%	Dramamine Original, Less Drowsy
Merck & Co.	20%	Promethazine-Sodium
Generic manufacturers	40%	Multiple brands

Pricing and Profitability

• Average retail price per 50-tablet pack: $4–$7.
• Margins are influenced by OTC retail channels, with manufacturer margins estimated at 20–30% before retailer markup.

Regulatory Impact

• In some regions, regulatory bodies like the European Medicines Agency (EMA) have signaled restrictive policies on older antihistamines, including reevaluation of OTC status, possibly reducing future sales.

Future Outlook

• Projected steady but modest growth, driven by demographic factors.
• Potential decline in mature markets due to competition and regulation.
• Opportunities in emerging markets expanding OTC access and travel trends.

What are the key risks and opportunities?

Risks:

• Regulatory reclassification could restrict sales.
• Competition from newer antihistamines offering safer profiles.
• Side effect profiles limiting use among certain demographics.

Opportunities:

• Expanded formulations (e.g., combination products).
• Growth in emerging markets.
• Increased awareness of motion sickness management.

Key Takeaways

Dimenhydrinate’s market sustains through consistent OTC demand driven by travel, aging populations, and broad accessibility. Market value is estimated at over $250 million globally, with slow but steady growth. Competitive and regulatory pressures pose risks, yet emerging markets and product innovation offer potential upside.

FAQs

1. Is dimenhydrinate still available OTC globally?
Yes, in many regions including North America, it remains an OTC medication, but regulatory reviews could alter this status.

2. What are the main competitors to dimenhydrinate?
Meclizine and promethazine serve as primary alternatives, often with fewer sedative effects.

3. How is the market size expected to change in the next five years?
Growth will likely be slow, influenced by demographic shifts and regulatory changes, with emerging markets presenting expansion opportunities.

4. What are the primary regulatory concerns?
Authorities may reevaluate aging antihistamines like dimenhydrinate for safety and side effect profiles, potentially leading to prescription-only status.

5. What factors influence pricing and profitability?
Retail margins, competition, regulatory costs, and regional pricing policies shape profit margins and overall revenue.

References

1. MarketsandMarkets, "OTC Anti-emetics Market," 2022.
2. European Medicines Agency, "Assessment of Antihistamines," 2021.
3. Johnson & Johnson investor presentations, 2022.
4. Industry reports, "Global OTC Medication Market Size," 2023.
5. U.S. Food and Drug Administration, "OTC Drug Review," 2022.